The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Janssen-Cilag; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Ipsen; Janssen-Cilag; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag
Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Dana E. Rathkopf
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Janssen; Lilly
 
Eleni Efstathiou
Honoraria - Astellas Pharma; Janssen-Cilag; Merck; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Sanofi; Tokai Pharmaceuticals
Research Funding - Janssen-Cilag
 
Gerhardt Attard
Honoraria - Astellas Pharma; Janssen; Janssen (I)
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate.
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems
Other Relationship - Institute of Cancer Research
 
David Olmos
Honoraria - Astellas Pharma (Inst); Bayer; Janssen
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bayer (Inst); Clovis Oncology; Daiichi Sankyo; Janssen; Janssen (Inst); MSD Oncology
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca Spain; Bayer; Ipsen; Janssen; Roche
 
Ji Youl Lee
No Relationships to Disclose
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Beigene; Fortis; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals; Ultragenyx Pharmaceuticals
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Janssen
 
Andrea Juliana Gomes
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Astellas Pharma; Bayer; Janssen Oncology
Research Funding - Bayer; Janssen Oncology; MSD Oncology; Roche
 
Guilhem Roubaud
No Relationships to Disclose
 
Marniza Saad
Honoraria - Astellas Pharma; AstraZeneca; Cipla; Eisai; Ipsen; Johnson&Johnson; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; BMS; Johnson&Johnson; Merck; MSD; Novartis; Viatris
Research Funding - Johnson & Johnson; MSD
 
Bogdan Zurawski
No Relationships to Disclose
 
Valerii Sakalo
No Relationships to Disclose
 
Gary Mason
Employment - Janssen Research & Development; Merck (I)
Stock and Other Ownership Interests - Johnson & Johnson; Merck (I)
Travel, Accommodations, Expenses - Janssen Research & Development
 
Adam del Corral
Employment - Celgene; Janssen Oncology
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb/Celgene; ecolab inc; Edwards Lifesciences; Intuitive Surgical; Johnson & Johnson/Janssen; Lilly
 
George C. Wang
Employment - Janssen Research & Development
Travel, Accommodations, Expenses - Janssen Research & Development
 
Daphne Wu
Employment - Johnson & Johnson/Janssen
 
Brooke Diorio
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - Janssen Research & Development; Janssen Research & Development
 
Angela Mennicke Lopez- Gitlitz
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Shahneen Kaur Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)